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Abstract 
Background: Colon carcinoma is one of the commonly tumors that threaten human beings as its highly morbidity 
and mortality. Recent evidences suggested that microRNA‑21 (miR‑21) played an important role in the development 
of colon carcinoma and might be a potential biological marker for the diagnosis and prognosis of colon carcinoma. 
However, the potential effect of miR‑21 based therapeutic studies in colon carcinoma remains to be fully elucidated.
Methods: In present study, we constructed an eukaryotic expression vector encoding antisense oligonucleotides 
against miR‑21 (termed as p‑miR‑21‑ASO) and the expression of miRNA‑21 in human colon cancer was detected by 
Real‑time PCR. To assess its possible effect on the proliferation and migration capacity of human colon carcinoma cells 
in vitro, CCK‑8 assay, colony formation assay and cell invasion, as well as migration assay, were performed respectively. 
Moreover, PTEN, one of target molecules of miRNA‑21, was analyzed by Western blot and Fluorescence activated cell 
sorter assay. Finally, the transduction of AKT and ERK pathways in human colon carcinoma cells was determined by 
Western blot.
Results: We found that transiently transfection of p‑miR‑21‑ASO could efficiently decrease the relative expression of 
miR‑21 in human colon carcinoma HCT116 cells, accompanied by impaired proliferation and clone formation. Further‑
more, we found that down‑regulation of miR‑21 also could significantly abrogate the invasion and migration capacity 
in vitro, as well as the expression of vascular endothelial growth factor which is critical for the metastatic capacity of 
colon carcinoma cells. Mechanistic evidence showed that down‑regulation of miR‑21 increased the expression of its 
target molecule PTEN in HCT116 cells. Finally, we revealed that the expression level of both phosphor‑ERK1/2 and 
phosphor‑AKT also were altered.
Conclusions: Therefore, our data suggested miR‑21 ASO against miR‑21 might be a useful strategy to alter the 
expression of miR‑21 in colon carcinoma cells, which was helpful for the development of miR‑21‑based therapeutic 
strategies against clinical colon carcinoma.
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Background
Colon carcinoma is one of the commonly tumors that 
threaten human beings as its highly morbidity and 
mortality [1, 2]. The development of colon carcinoma is a 
complex process that requires a series of integrated steps 
including cellular neoplastic transformation, unlimited 
growth, and the acquisition of invasive/metastatic prop-
erties, as well as immunologic escape [3, 4]. Although 
extensive investigation explored some important fac-
tors of colon carcinoma, the effect of various treatment 
approaches including surgical operation, chemotherapy 
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and immune cell based therapy remains limited because 
of the complex process of development of colon carci-
noma [5, 6]. Thus, new strategies are still required for 
achieving effective treatment of colon carcinoma, which 
might ultimately aid the clinical therapy for colon carci-
noma patients.
MiRNA-21 is an important member of miRNAs, which 
located on chromosome 17q23-2 overlapping with the 
TMEM49 gene and is regulated through its promoter 
containing binding sites for AP-1 and PU.1 transcription 
factors [7]. Numbers of researches have been reported 
on miRNA-21 play a critical role in the development of 
kinds of tumors via a variety of molecular mechanisms 
[8, 9]. To colon carcinoma, recent evidences also sug-
gested that miR-21 as an oncomiRNA molecule played 
an important regulator role in the development of colon 
carcinoma including the proliferation, invasion and 
metastatic potential of cancer cells. For instance, Drusco 
et al. reported that miRNA-21 might be a potential meta-
static signature of colon cancer, and a useful marker dis-
tinguishing colon cancer recurrences to lymph nodes 
from liver, or colon cancer liver metastasis from primary 
hepatic tumor [10]. Similarly, Roy et al. found that over-
expression of miR-21 could enhance the growth of colon 
cancer cells in  vivo through down-regulation of PTEN 
[11]. Nangia-Makker et  al. further reported that met-
formin combined with 5-fluorouracil and oxaliplatin in 
the treatment of colon carcinoma induced cell apoptosis 
in chemo-resistant HCT116 cells, which was associated 
with reduced expression of miRNA-21 [12]. In addition, 
Li et  al. showed that miRNA-21 might be a useful bio-
logical marker which was closely related to the diagnosis 
and prognosis of colon carcinoma [7]. These researches 
indicated the important role of miR-21 in the develop-
ment and the diagnosis, as well as prognosis of colon 
carcinoma. However, whether miR-21 may be used as a 
potential target in the biological therapy against colon 
carcinoma remains to be further elucidated.
To this aim, in present study, we constructed an eukar-
yotic expression vector encoding antisense oligonucleo-
tides (ASOs) against miR-21 (termed as p-miR-21-ASO) 
and assessed its possible effect on the proliferation and 
migration capacity of human colon carcinoma cells and 
explored the related mechanism, which might be helpful 
for the development of miR-21-based therapeutic strate-
gies against clinical colon carcinoma.
Results
MiRNA‑21 ASO reduced the proliferation of human colon 
carcinoma cells
To investigate the possible effect of miR-21-based thera-
peutic strategy against human colon carcinoma cells, we 
firstly identified the relative expression of miRNA-21 in 
a set of three colon carcinoma cell lines and a normal 
colonic cell line using Real-time PCR assay. As shown 
in Additional file  1: Figure S1, miRNA-21 levels were 
up-regulated in all carcinoma cell lines compared with 
normal control (p  <  0.05), which was consistent with 
previous report [7]. Then we constructed an eukaryotic 
expression vector encoding antisense oligonucleotides 
(ASOs) against miR-21 (termed as p-miR-21-ASO), and 
then transiently transfected into colon carcinoma cell line 
HCT116 cells (Fig.  1a). The transfection efficiency was 
verified by detecting the expression of GFP by fluores-
cence microscopy. As shown in Fig. 1b, the mean propor-
tion of GFP positive cells was about 70% in each group at 
48 h after transfection. As expected, real-time PCR anal-
ysis showed that the expression of miRNA-21 in p-miR-
21-ASO transfection group was significantly decreased 
compared with that in p-Cont transfection group (Fig. 1c, 
p < 0.05), suggesting that miR-21 ASO could significantly 
reduce the expression of intrinsic miR-21 in colon carci-
noma cells.
Importantly, we found that the proliferation of HCT116 
was significantly decreased in p-miR-21-ASO transfected 
groups compared with that in control group (Fig.  1d, 
p < 0.05). To further confirm the effect of miR-21 ASO on 
the growth of colon carcinoma cells, we also detected the 
possible influence of miR-21 ASO on another colon car-
cinoma cell line SW620 cells which expressed high level 
of intrinsic miR-21 and obtained similar results (Addi-
tional file 2: Figure S2). Combining these data indicated 
that miR-21 ASO could effectively down-regulate the 
expression of miR-21 and successively reduce the prolif-
eration capacity of colon carcinoma cells.
MiRNA‑21 ASO reduced the colony formation capacity 
of human colon carcinoma cells
Next, we further investigate the possible effect of miR-21 
ASO on the colony formation capacity of human colon 
carcinoma cells, which was closely related to the growth 
of cancer cells. As shown in Fig.  2, we found that both 
the volume and number of formative colonies of HCT116 
cells in p-miR-21-ASO transfected group was also obvi-
ously decreased than those in p-Cont transfected group 
(p < 0.05), indicating that down-regulation of miR-21 by 
ASO also could impair the colony formation capacity of 
human colon carcinoma cells.
MiRNA‑21 ASO impaired the invasion and migration ability 
of human colon carcinoma cells
Then, we further investigated whether down-regulation 
of miR-21 by miR-21 ASO could affect the invasion abil-
ity of colon cancer cells in  vitro. As shown in Fig.  2a, 
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b, transwell assay showed that the invasion cell num-
ber in p-miR-21-ASO transfected group was obviously 
decreased compared with that in p-Cont transfected 
group (Fig. 3a, b, p < 0.5). To analysis the possible effect 
of down-regulation of miR-21 on the migration capacity 
of colon carcinoma cells, scratch wound assay was also 
performed. Data showed that the migration capacity of 
HCT116 cells was also impaired in p-miR-21-ASO trans-
fected group (Fig. 3c, d, p < 0.5).
Vascular endothelial growth factor (VEGF) is endothelial 
cell specific heparin-binding growth factor, which is criti-
cal for the proliferation and metastatic potential of colon 
carcinoma cells [13, 14]. We further detected the VEGF 
protein expression and found that its expression was 
decreased in p-miR-21-ASO transfected group compared 
with p-Cont transfected group (Fig. 3e, f, p < 0.5). Com-
bining these data suggested that miR-21 ASO could impair 
the potential metastatic capacity of colon carcinoma cells.
MiRNA‑21 ASO reversed PTEN expression in human colon 
carcinoma cells
Recent studies have shown that PTEN, a critical tumor 
suppressor in the occurrence and progression of various 
tumors, was one of target molecules of miR-21 [15–17]. 
Moreover, PTEN also could inhibit angiogenesis that 
associated with decreased expression of VEGF [18]. To 
investigate the possible mechanism of down-regulation 
of miRNA-21 by miR-21 ASO in the proliferation and 
migration of colon carcinoma, we further detected the 
expression of PTEN in human colon carcinoma HCT116 
cells. As shown Fig. 4a, b, the expression of PTEN protein 
was significantly elevated in p-miR-21-ASO transfected 
group compared with that in p-Cont transfected group 
(p  <  0.5). To further verify the expression of PTEN, we 
also analyzed the expression of PTEN protein in HCT116 
cells using FACS analysis and similar result was obtained 
(Fig. 4c, d, p < 0.5).
Fig. 1 MiRNA‑21 ASO reduced the proliferation of human colon carcinoma cells. a The schematic of a eukaryotic expression vector encoding 
antisense oligonucleotides against miR‑21 (termed as p‑miR‑21‑ASO). b Human colon carcinoma cell line HCT116 cells were cultured in 96 well 
plate and transiently transfected with p‑miR‑21‑ASO or p‑Cont (5 μg). After 48 h, the expression of GFP protein was observed by fluorescent micros‑
copy. c The expression level of miR‑21 in HCT116 cells was also determined by Real‑time PCR assay and calculated. d At indicated time point, the 
proliferation of HCT116 cells in p‑miR‑21‑ASO transfected group and p‑Cont group also were detected by CCK‑8 assay. One representative of three 
experiments was shown. *p < 0.05.
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MiRNA‑21 ASO altered the transduction of AKT and ERK 
pathways in human colon carcinoma cells
Recent literatures demonstrated that transduction of 
AKT and ERK pathway was important for the growth and 
metastasis of various cancer cells including colon car-
cinoma cells [19, 20]. Moreover, PTEN also was closely 
related to the transduction of AKT and ERK pathway in 
various cancers [21]. Our above data showed that miR-21 
ASO could elevate the expression of PTEN. Then, we fur-
ther analyzed the possible change of transduction of AKT 
and ERK pathway in human colon carcinoma cells. Data 
showed that the level of total AKT and ERK did not show 
significant change in each group (Fig.  5a, b, p  >  0.05). 
However, the level of phosphor-AKT in p-miR-21-ASO 
transfected group was decreased obviously (Fig.  5a, b, 
p  <  0.05). Similarly, the level of phosphor-ERK1/2 was 
also decreased significantly (Fig.  5a, b, p  <  0.05). These 
results suggested that down-regulated expression of 
miRNA-21 by miR-21 ASO could reverse the expression 
of PTEN and successively alter the transduction of AKT 
and ERK signaling pathways, which ultimately impaired 
the proliferation and metastasis potential of human colon 
carcinoma cells.
Discussion
In present study, we firstly showed that miR-21 ASO 
could reduce the expression of miR-21 in human colon 
carcinoma cells. Moreover, miR-21 ASO also could 
impair the proliferation and colony formation capacity, as 
well as metastatic potential, of human colon carcinoma 
cells, which was related to altered expression of PTEN 
and successive transduction of AKT and ERK pathway. 
These data suggested that miR-21 might be a potential 
target for the therapeutic strategy against clinical colon 
carcinoma.
Accumulating literatures suggested that miR-21 was a 
critical regulator in the development of a various type of 
cancers [22–24]. Moreover, miR-21 was also reported as 
a potential biomarker for diagnosis and prognosis of clin-
ical colon carcinoma [25, 26]. Recent researches further 
suggested that antisense oligonucleotides (ASO) against 
specific miRNA molecules might be a useful strategy for 
the development of biological therapy in clinical diseases 
including cancers. Such as, our recent evidence showed 
that ASO against miR-155, which was highly expressed in 
lung tissues in acute lung injury (ALI), could enhance the 
recovery of ALI [27]. To cancers, Li et  al. reported that 
Fig. 2 MiRNA‑21 ASO reduced the colony formation capacity of human colon carcinoma cells. Human colon carcinoma cell line HCT116 cells were 
transiently transfected with p‑miR‑21‑ASO or p‑Cont (5 μg). a At indicated time point, the colony diameter was analyzed. b After 13 days, then 
colony numbers were analyzed by crystal staining and calculated (c). Data represent as mean ± SD of three independent experiments. *p < 0.05.
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miR-150 ASO could inhibit proliferation of lung cancer 
cells by regulating miR-150 expression [28]. Moreover, 
Qiang et  al. demonstrated that ASO against miR-20a 
could inhibit the invasion and migration of prostate 
cancer cells [29]. In present study, we found that miR-21 
ASO could reduce the expression of miR-21 in human 
colon carcinoma cells. Moreover, the growth and colony 
formation capacity of colon carcinoma cells also were 
Fig. 3 MiRNA‑21 ASO impaired the invasion and migration ability of human colon carcinoma cells. Human colon carcinoma cell line HCT116 
cells were transiently transfected with p‑miR‑21‑ASO or p‑Cont (5 μg). Then, the ability of invasion of cells was analyzed by Transwell assay (a) and 
calculated (b). c The ability of migration of cells also was determined by Wound‑healing assay and calculated (d). e HCT116 cells were transiently 
transfected with p‑miR‑21‑ASO or p‑Cont (5 μg). 48 h later, the protein expression of VEGF was analyzed by western blotting and calculated (f). One 
representative of three experiments was shown. *p < 0.05.
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significantly impaired. Similarly, Li et  al. reported that 
miR-21 ASO could abrogate the expression of miR-21 
and reduce the growth of EGFR-TKI-sensitive human 
lung adenocarcinoma cells [30]. These data suggested 
that miR-21 might be a useful target for the develop-
ment of therapeutic strategy against colon carcinoma. 
Therefore, successive research work on the effect of miR-
21 ASO in the growth of human colon carcinoma cells 
Fig. 4 MiRNA‑21 ASO reversed PTEN expression in human colon carcinoma cells. Human colon carcinoma cell line HCT116 cells were transiently 
transfected with p‑miR‑21‑ASO or p‑Cont (5 μg). 48 h later, the protein expression of PTEN was analyzed by Western blotting (a) and calculated 
(b). c The expression of PTEN also analyzed by FACS and then the mean fluorescence intensity (MFI) was calculated (d). Gray line p‑Cont transfected 
group, black line p‑miR‑21‑ASO transfected group. One representative of three experiments was shown. *p < 0.05.
Fig. 5 MiRNA‑21 ASO altered the transduction of AKT and ERK pathways in human colon carcinoma cells. Human colon carcinoma cell line HCT116 
cells were transiently transfected with p‑miR‑21‑ASO or p‑Cont (5 μg). 48 h later, the level of total and phosphor‑AKT and phosphor‑ERK1/2 were 
analyzed by Western blotting (a) and calculated (b). One representative of three experiments was shown.*p < 0.05.
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in vivo was much valuable for the validation of the devel-
opment of miR-21 targeted based therapeutic strategy 
against colon carcinoma.
PTEN is a discovered well-known tumor suppres-
sor gene and involved in the regulation of various type 
of cancers including colon carcinoma [31–33]. For 
instance, Setia et  al. reported that the expression of 
PTEN was significantly decreased in carcinogenic con-
dition in colon cancer [34]. Jaqan et  al. further showed 
that overexpression of PTEN could abrogate the dis-
semination and growth of colon carcinoma cells [35]. 
In this study, we found that miR-21 ASO could reverse 
the expression of PTEN, which was a target of miR-21, 
accompanied by reduced metastatic potential of colon 
carcinoma cells. Furthermore, the transduction of AKT 
and ERK pathway also were altered. Consistently, Setia 
et al. found that the transduction of AKT and ERK path-
way was elevated in colon cancer [36]. Auyeung et  al. 
further showed that inhibition of AKT and ERK path-
way transduction could induce the apoptosis of colon 
cancer cells [37, 38]. Most recently, Sun et  al. reported 
that PTEN could reduce the proliferation of colon carci-
noma through regulating the transduction of AKT path-
way [39]. In addition, some studies reported that PTEN 
also could regulate the expression of VEGF, which was 
important for the carcinogenesis of cancers [40, 41]. 
Such as, Tian et  al. reported that PTEN could regulate 
the expression of VEGF through AKT pathway in human 
hepatoblastoma cells [18]. Similarly, we also found that 
miR-21 ASO could reduce the expression of VEGF in 
colon carcinoma cells. Therefore, combing these data 
further highlighted the critical role of PTEN pathway in 
the development of colon carcinoma. Taken together, we 
presumed that miR-21 ASO could reverse the expression 
of PTEN and successively alter the transduction of AKT 
and ERK pathway, accompanied by reduced expression 
of VEGF. Finally, it should be pointed out that we did 
not exclude the potential contribution of other target 
molecules of miR-21, which did not been investigated in 
present study, to the effect of miR-21 ASO on the prolif-
eration and migration capacity of colon carcinoma cells. 
In fact, successive research work on these target mole-
cules including PDCD4 [42], was also important for the 
elucidation of effect of miR-21 ASO on colon carcinoma 
cells.
In summary, our study showed miR-21 ASO could 
effectively reduce the expression of miR-21 and succes-
sively impair the proliferation and migration of human 
colon carcinoma cells, which was closely related to 
altered expression of PTEN and transduction of AKT and 
ERK pathway, indicating that miR-21 might be a potential 
target and be useful for the development of new thera-
peutic strategy against clinical colon carcinoma.
Methods
Materials
McCoy 5A was purchased from Sigma. T4 DNA ligase 
was purchased from Fermentas. The pcDNA™6.2-GM/
EmGFP-miR, pcDNA™6.2-GM/EmGFP-miR-neg-con-
trol plasmid and Lipofectamine 2000 were purchased 
from Invitrogen. Trizol reagent was purchased from 
Takara. RevertAid First Strand cDNA Synthesis kits 
were purchased from Thermo. Antibodies against VEGF, 
PTEN, AKT, and phospho-AKT were purchased from 
Abcam. Antibodies against GAPDH, ERK1/2 and phos-
pho-ERK1/2 were purchased from Cell Signaling Tech-
nology. Cell counting kit-8 reagent was purchased from 
Boster. Transwell chambers were purchased from Costar. 
SYBR® Premix Ex Taq™ II was purchased from Takara. 
C1000™Thermal Cycler and S1000™Thermal Cycler were 
purchased from BIO-RAD. Flow cytometry from Beck-
man Coulter.
Vector construction
Designed antisense oligonucleotides targeting mature 
miRNA-21 sequence (UAGCUUAUCAGACUGAUGU 
UGA), sense strand: 5′-TGCTTCAACATCAGTCTGAT 
AAGCTATTTTTG-3′, antisense strand: 5′-CCTGCAAA 
AATAGCTTATCAGACTGATGTTGA-3′. The pcDNA-
6.2-miRNA-21-ASO vector was constructed through 
annealing synthesized ds oligonucleotides connected to 
pcDNA™6.2-GM/EmGFP-miR. Plasmid sequences were 
confirmed by sequencing.
Cell culture and transient transfection
Human colon carcinoma cell lines HCT-116, HT29, 
SW620 and normal colonic cell line FHC were obtained 
from National Rodent Laboratory Animal Resource 
(Shanghai, China). All the cancer cells were cultured in 
McCoy 5A, RPMI-1640 or Leibovitz’s L-15 medium 
containing 100  IU/mL penicillin, 100  μg/mL strepto-
mycin, 20 mM glutamine and 10% heat-inactivated fetal 
bovine serum (FBS). All cells were cultured in a humidi-
fied atmosphere of 5% CO2 at 37°C. For transfection, cells 
were seeded at 70% confluence and 12 h later, cells were 
transfected with pcDNA-6.2-miRNA-21-ASO vector or 
pcDNA6.2-miR-neg-control vector with Lipofectamine 
2000 according to the manufacturer’s instruction. 
Cells were harvested after indicated time for following 
experiments.
Quantitative Real‑time PCR for miRNA‑21
Total RNA was extracted from cells with Trizol and 
reverse transcribed using RevertAid First Strand cDNA 
Synthesis kits according to the manufacturer’s instruc-
tions. The resulting complementary DNA (cDNA) was 
used for real-time PCR using the SYBR® Premix Ex Taq™ 
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II with triplicates. Data collection was performed on the 
CFX96™ Real-Time System. All calculations were nor-
malized to an endogenous control, GAPDH. The relative 
quantitation value for the target gene compared to its cal-
ibrator is expressed as 2−ΔΔCt. Aliquots of reaction mix-
ture following conditions: initial denaturation at 95°C for 
5 min followed by 40 cycles of 95°C for 15 s, 60°C for 30 s.
Cell counting kit‑8 assay
HCT116 cells/SW620 cells were seeded in 96-well plates 
at 1 × 104/well with triplicate and infected with pcDNA-
6.2-miRNA-21-ASO (p-miR-21-ASO) or pcDNA6.2-
miR-Ctrl (p-Cont). At indicated time points, cells were 
detected using cell counting kit-8 (CCK-8) assay. 20  µL 
CCK-8 solution was added into each well. After 3  h of 
incubation at 37°C. The absorbance was measured with a 
spectrophotometer at 450 nm with 600 nm as a reference.
Colony formation assay
Collected infected 72 h HCT116 cells as above described. 
Cells were trypsinized to single cell suspension and 
seeded in 6-well plates at 1,000/well for clone forming 
experiment. Then, the cells were incubated in a humidi-
fied atmosphere of 5% CO2 at 37°C. The medium were 
renewed every 5  days. 13  days later, the colonies were 
stained with crystal violet and the colony diameter and 
number was statistically analyzed.
Cell invasion and migration assay
Cell invasion was performed by Matrigel invasion assay. 
8-mm pore size-culture inserts were first coated with 
Matrigel (BD Bioscience). HCT116 cells transfected 
with p-miR-21-ASO or p-Cont for 48 h were harvested, 
suspended (5 × 104/well) in 200 µL serum-free medium 
and then seeded on the upper compartment of cham-
ber. The lower chamber was added 500  µL McCoy 5A 
media with 10% FBS. After 48 h incubation, the cells in 
the bottom chamber that had invaded were stained with 
crystal violet and counted using fluorescence microscopy 
(100× magnification). In addition, Wound healing assay 
was also performed for analysis of cell migration in vitro. 
Cells were cultured as previously described. Then, a 
single scratch was made in the center of cell monolayer 
using a 1,000 tip. The scratch areas were visualized under 
fluorescence microscope with a magnification 100× and 
the migrated cells were counted. Three independent 
experiments were performed with triplicate wells.
Western blotting
Cells were lysed with RIPA lysis buffer [1  mM phenyl-
methylsulfonyl fluoride (PMSF), 1× Protease Inhibitors, 
1× Phosphatase Inhibitors] on ice for 30 min. Total cel-
lular proteins were assayed using Bio-Rad protein assay 
reagent. Equal amounts of protein were subjected to 
SDS-PAGE electrophoresis, then electrophoretic trans-
fer to nitrocellulose membranes. Membranes were 
blocked with 5% nonfat dry milk in PBS with 0.1% 
Tween20 for 1 h at 37°C, Then incubated with antibod-
ies VEGF, PTEN, phosphor-AKT, total AKT, phospho-
ERK1/2, and total ERK1/2 at 4°C for overnight. Finally, 
incubated with horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h. Results were analyzed by ECL 
detection system.
FACS analysis on PTEN expression
Collected infected 72  h HCT116 cells and then fixed 
with 4% paraformaldehyde for 10 min and then flushing 
with twice. Cells were blocked with 5% nonfat dry milk 
in PBS with 0.1% Tween 20, and incubated with antibod-
ies against PTEN for 30 min at 22°C after flushing with 
twice. The secondary antibody used was Alexa Fluor® 
488 goat anti-rabbit IgG (H  +  L) at 1/500 dilution for 
30 min at 22°C. Eventually the stained cells were analyzed 
by a flow cytometer.
Statistical analysis
All values were represented as the mean ±  SD from at 
least three independent experiments. Student’s T-test for 
two groups or one-way analysis of variance (ANOVA) 
for three or more groups were performed to evaluate the 
statistical significance by using GraphPad Prism 5 soft-
ware. P values less than 0.05 were considered statistically 
significant.
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